Delisting riskPopularity #4,715
Satellos Bioscience (MSLE)
Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.
$9.02
After hours+0.02 (+0.20%)
At close$9.00(−1.96%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 596.51% | 7.68M shares | |
|---|---|---|---|
| 26 holders · as of Jun 30, 2026 | |||
| Adds to | 596.51% | ||
1.29M company shares as of Sep 10, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 596.51%; nothing is left for Other.
13F, as of Jun 30, 2026
26 holders · 7.68M shares · 2 new positions · 8 increased · 6 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Franklin Resources Inc | 938.7K | 72.86% | 0 | Aug 13, 2026 |
| Siren, L.L.C. | 892.1K | 69.25% | 0 | Aug 13, 2026 |
| Vivo Capital, LLC | 813.7K | 63.16% | 0 | Aug 14, 2026 |
| Point72 Asset Management, L.P. | 682.7K | 52.99% | −8.1K | Aug 14, 2026 |
| Sphera Funds Management Ltd. | 652.6K | 50.66% | +163.4K | Aug 14, 2026 |
| Woodline Partners LP | 500.4K | 38.85% | 0 | Aug 14, 2026 |
| Stonepine Capital Management, LLC | 491.6K | 38.16% | +391.6K | Aug 17, 2026 |
| Suvretta Capital Management, LLC | 475.0K | 36.87% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.